A Phase II Study of CCX282-B in Patients With Celiac Disease
NCT ID: NCT00540657
Last Updated: 2025-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2007-10-31
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
NCT02637141
Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.
NCT01990885
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
NCT06982963
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
NCT05353985
PTG-100 for Patients With Celiac Disease
NCT04524221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CCX282-B
250mg capsule, twice daily, 13 weeks
2
Placebo
Placebo capsule, twice daily, 13 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CCX282-B
250mg capsule, twice daily, 13 weeks
Placebo
Placebo capsule, twice daily, 13 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Established diagnosis of celiac disease
* Subject has been following a strict gluten-free diet for at least 24 months
Exclusion Criteria
* Use of any immunosuppressants, TNF inhibitors, or natalizumab during the 12 weeks prior to study randomization
* Use of steroids during the 4 weeks prior to study randomization
* Receipt of an experimental treatment for any disease within 4 weeks prior to randomization
* Known IgE-mediated atopy or allergy or anaphylactic reactions to gluten
* The subject suffers from a condition that carries a risk at endoscopy or is on anticoagulant treatment
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Finn-Medi Research Ltd, Outpatient Clinic
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL009_282
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.